Outcomes of Methadone and Buprenorphine Maintenance Treatments in Opioid Use Disorder Patients: A Retrospective Cohort Study
- 6 July 2026
- journal article
- research article
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 61 (13) , 2312-2319
Abstract
Opioid use disorder (OUD) is a chronic and long-lasting condition that presents one of the most critical health issues. It can lead to physical and mental health consequences for individuals, famil...Keywords
This publication has 25 references indexed in Scilit:
- Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studiesThe Lancet Psychiatry, 2023
- Non-fatal overdose risk during and after opioid agonist treatment: A primary care cohort study with linked hospitalisation and mortality recordsThe Lancet Regional Health - Europe, 2022
- Relapse risk revealed by degree centrality and cluster analysis in heroin addicts undergoing methadone maintenance treatmentPsychological Medicine, 2021
- Global patterns of opioid use and dependence: harms to populations, interventions, and future actionThe Lancet, 2019
- Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting FormulationsJournal of Addiction Medicine, 2019
- Factors associated with concurrent heroin use among patients on methadone maintenance treatment in Vietnam: A 24-month retrospective analysis of a nationally representative sampleInternational Journal of Drug Policy, 2018
- Retention in medication-assisted treatment for opiate dependence: A systematic reviewJournal of Addictive Diseases, 2015
- Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependenceCochrane Database of Systematic Reviews, 2014
- A Meta-Analysis of Retention in Methadone Maintenance by Dose and Dosing StrategyThe American Journal of Drug and Alcohol Abuse, 2009
- 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trialThe Lancet, 2003